FDA Approves Groundbreaking mRNA Vaccine Booster for Adults 50+, Boosting Immunity and Protecting Against Chronic Health Risks
The U.S. Food and Drug Administration has approved mFLUSIVA, manufactured by Moderna, as the first messenger RNA flu vaccine for adults aged 50 and older ahead of the 2026–2027 flu season. While the shot earned standard approval for individuals 50 to 64, it secured accelerated clearance for those 65 and older pending further data. FDA … Read more